Wedbush Predicts Reduced Earnings for Compass Therapeutics

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Research analysts at Wedbush reduced their FY2028 earnings per share (EPS) estimates for Compass Therapeutics in a report released on Tuesday, April 1st. Wedbush analyst R. Driscoll now forecasts that the company will earn $1.17 per share for the year, down from their previous estimate of $1.36. Wedbush has a "Outperform" rating and a $8.00 price target on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.36) per share.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01).

Several other research analysts also recently commented on the company. Leerink Partners upgraded Compass Therapeutics from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Leerink Partnrs raised shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st. HC Wainwright upped their price objective on shares of Compass Therapeutics from $10.00 to $24.00 and gave the company a "buy" rating in a report on Friday. Piper Sandler initiated coverage on shares of Compass Therapeutics in a research note on Wednesday, February 19th. They set an "overweight" rating and a $12.00 target price for the company. Finally, D. Boral Capital reiterated a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Compass Therapeutics presently has an average rating of "Buy" and an average target price of $13.38.

Remove Ads

Compass Therapeutics Stock Performance

Compass Therapeutics stock traded down $0.03 during midday trading on Thursday, reaching $1.55. 608,780 shares of the company's stock were exchanged, compared to its average volume of 819,738. The stock's 50-day simple moving average is $2.73 and its 200 day simple moving average is $2.11. The firm has a market cap of $213.65 million, a price-to-earnings ratio of -4.18 and a beta of 1.40. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08.

Insider Buying and Selling

In other Compass Therapeutics news, insider Jonathan Anderman acquired 20,000 shares of the business's stock in a transaction on Monday, April 7th. The stock was purchased at an average price of $1.54 per share, with a total value of $30,800.00. Following the acquisition, the insider now directly owns 21,000 shares of the company's stock, valued at approximately $32,340. This trade represents a 2,000.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 28.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CMPX. Rhumbline Advisers increased its stake in Compass Therapeutics by 3.1% during the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company's stock worth $187,000 after acquiring an additional 3,822 shares during the period. Invesco Ltd. grew its holdings in shares of Compass Therapeutics by 11.3% during the 4th quarter. Invesco Ltd. now owns 39,483 shares of the company's stock worth $57,000 after purchasing an additional 4,018 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Compass Therapeutics by 2.6% in the fourth quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company's stock worth $345,000 after purchasing an additional 6,041 shares during the period. ProShare Advisors LLC raised its stake in Compass Therapeutics by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock valued at $42,000 after purchasing an additional 9,451 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Compass Therapeutics by 31.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company's stock worth $69,000 after purchasing an additional 11,326 shares during the period. 68.43% of the stock is currently owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.